# National Biologics Facility (NBF)

> Australia's national facility for recombinant protein and biologics production, based at the Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, St Lucia, Brisbane. NBF produces recombinant protein for research, industrial and therapeutic use, from research-grade protein supply through to Phase I clinical-grade drug substance.

National Biologics Facility (NBF) supports academic and industry clients developing monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), radioligand therapeutics and radiopharmaceutical precursors, recombinant vaccines, Fc-fusion proteins, bispecifics, nanobodies and therapeutic enzymes. Beyond therapeutic programmes, NBF routinely produces research-grade and reagent proteins, antigens, recombinant enzymes, and diagnostic and structural-biology targets for academic, industrial and government users, with no requirement to progress to clinical development. NBF is a node of Therapeutic Innovation Australia (TIA) and is supported by the National Collaborative Research Infrastructure Strategy (NCRIS). Operations run under an ISO 9001 quality management system, with Phase I clinical-grade manufacture up to 50L at PC2.

Contact: nbf@uq.edu.au, AIBN Building 75, University of Queensland, St Lucia, Brisbane QLD 4072, Australia.

## Capabilities
- [Biologic modalities](https://www.nationalbiologicsfacility.com/cap-modalities.html): mAbs, ADCs, radioligands and radiopharmaceutical precursors, recombinant vaccines, Fc-fusions, bispecifics, nanobodies and therapeutic enzymes
- [Discovery and protein engineering](https://www.nationalbiologicsfacility.com/cap-discovery.html): antibody discovery via phage display, nanobody campaigns, protein engineering, antibody-drug conjugates and bioconjugation
- [Molecular engineering and cloning](https://www.nationalbiologicsfacility.com/cap-molecular.html): high-throughput cloning, a broad vector suite and endotoxin-free plasmid production
- [Recombinant protein expression](https://www.nationalbiologicsfacility.com/cap-expression.html): multi-host expression in E. coli, Pichia yeast, baculovirus/insect and mammalian (CHO, HEK293) systems
- [Process development and scale-up](https://www.nationalbiologicsfacility.com/cap-process.html): upstream and downstream process development, formulation and scale-up from 1L to 50L bioreactors
- [Bioanalytics and characterisation](https://www.nationalbiologicsfacility.com/cap-bioanalytics.html): identity, purity, intact mass, sequencing, glycan profiling, stability and release-grade assays
- [Phase I clinical-grade manufacturing](https://www.nationalbiologicsfacility.com/cap-manufacturing.html): 50L PC2 scale-up, ISO 9001 quality, master cell banking and drug substance release for first-in-human trials

## About
- [Our team](https://www.nationalbiologicsfacility.com/team.html): protein scientists, bioprocess engineers, and analytical and quality experts
- [Case studies](https://www.nationalbiologicsfacility.com/case-studies.html): biologics programmes from discovery to Phase I manufacture
- [Publications](https://www.nationalbiologicsfacility.com/publications.html): peer-reviewed research enabled by NBF
- [Contact](https://www.nationalbiologicsfacility.com/contact.html): project enquiries and location

## News and events
- [News and insights](https://www.nationalbiologicsfacility.com/news.html): milestones, partnerships and research breakthroughs
- [Protein Australia 2026](https://www.nationalbiologicsfacility.com/proteinaustralia2026.html): national meeting on protein science and technology, 17-18 August 2026, Brisbane Convention and Exhibition Centre
- [Events](https://www.nationalbiologicsfacility.com/events.html): upcoming NBF events